Breaking News Instant updates and real-time market news.

GILD

Gilead

$68.17

-2.01 (-2.86%)

, RHHBY

Roche

$0.00

(0.00%)

05:21
12/10/18
12/10
05:21
12/10/18
05:21

Gilead appoints Roche CEO Daniel O'Day as CEO, chairman

Gilead Sciences announced that its board has named Daniel O'Day chairman of the board and CEO, effective March 1, 2019. O'Day is currently the CEO of Roche Pharmaceuticals (RHHBY). He has held the position since 2012, and prior to that led Roche Diagnostics. The Board has also appointed Gregg Alton as interim CEO for the period of January 1, 2019 until O'Day's start date of March 1, 2019. Alton has held a number of executive positions at Gilead over the past 20 years, with experience in legal, medical affairs, policy and commercial. He previously served as general counsel and in August of this year, was appointed Chief Patient Officer.

GILD

Gilead

$68.17

-2.01 (-2.86%)

RHHBY

Roche

$0.00

(0.00%)

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

GILD Gilead
$68.17

-2.01 (-2.86%)

12/02/18
PIPR
12/02/18
NO CHANGE
Target $12
PIPR
Overweight
Alpine Immune Sciences' ALPN-101 active in GvHD, CTA by YE18, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Alpine (ALPN) presented two posters at ASH on proprietary variable Immunoglobulin Domain technology. In vivo data at ASH showed single doses enhanced survival in GvHD models compared to Bristol Myer's (BMY) Nujolix, he notes, adding that a CTA for ALPN-101 by YE18 should enable healthy volunteer data and lead to a Phase II GvHD start next year. The analyst also points out that Alpine presented novel Transmembrane ImmuneModulatory Proteins that can be engineered into T cells to enhance response in immunosuppressive environments. Importantly these strategies differ from TIP technology partnered to Kite (GILD) and offer further partnering opportunity, Tenthoff contends. He reiterates an Overweight rating and $12 price target on Alpine's shares.
11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
10/31/18
MZHO
10/31/18
NO CHANGE
Target $94
MZHO
Buy
Mizuho says concerns over UnitedHealth program impact on Gilead seem unwarranted
Mizuho analyst Salim Syed blames UnitedHealth's (UNH) introduction of a new a program, called "My ScriptRewards," that will try to convince plan participants to take a cheaper HIV regimen in return for $500 in debit cards for the weakness in shares of Gilead (GILD). However, the analyst views the worries as unwarranted, noting that Cimduo is the "common thread" between all of the regimens that UnitedHealth's program calls out and it is an inferior drug to Gilead's Biktarvy. Biktarvy is the backbone of the number one recommended regimen according to HHS treatment guidelines, noted Syed, who keeps a Buy rating and $94 price target on Gilead shares.
10/31/18
EVER
10/31/18
NO CHANGE
EVER
Outperform
Gilead sales not at risk from UnitedHealth promotions, says Evercore ISI
Evercore ISI analyst Umer Raffat attributes the pullback today in shares of Gilead Sciences (GILD) to concerns over the company's HIV franchise given UnitedHealth's (UNH) promotions of cheaper alternatives. UnitedHealth (UNH) is offering a rewards plan to patients starting with HIV medications to help promote the use of lower priced drugs, Jefferies analyst Michael Yee pointed out earlier today in a research note. Raffat, however, does not see risk to Gilead's sales from the promotions. UnitedHealth's is proposing a switch to two separate tablets, which is not in the HIV guidelines today, says the analyst. He keeps an Outperform rating on Gilead shares, which are down 6% to $68.00 in afternoon trading.
RHHBY Roche
$0.00

(0.00%)

11/26/18
SBSH
11/26/18
NO CHANGE
SBSH
Citi opens positive catalyst watch on Roche
Citi analyst Andrew Baum opened a positive catalyst watch on Roche (RHHBY) shares saying he expects CD20-TCB data at the American Society of Hematology meeting to report overall response rate and complete response "materially higher" than the 38% and 24% reported in the abstract as doses are escalated from 1800 microgams up to 60 milligrams. Further, unlike the Genentech and Regeneron (REGN) antibodies, Roche has seen no neurotoxicity with their CD20-TCB, says Baum. The analyst anticipates that Roche's CD20-TCB will look superior to Genentech's CD20/CD3 and Regeneron's REGN1979 on safety. He keeps a Neutral rating on Roche.
11/19/18
GSCO
11/19/18
DOWNGRADE
GSCO
Buy
Roche downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Katherine Alexakis removed Roche from her firm's Conviction List but keeps a Buy rating on the shares. A number of "sentiment overhangs" in the near-term, namely the launch of U.S. biosimilars, combined with a lack of tangible catalysts could limit share upside, says the analyst.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/13/18
LEER
11/13/18
INITIATION
Target $18
LEER
Outperform
AC Immune initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started AC Immune with an Outperform and $18 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding AC Immune, Goodman notes that it has a diversified pipeline of drug candidates and diagnostics for Alzheimer's disease led by a late stage antibody with crenezumab, and has strong partners with Roche (RHHBY) for crenezumab, Johnson & Johnson (JNJ) for Anti-Tau vaccine, Biogen (BIIB) for alphasynuclein-PET tracer diagnostic, and Piramal for TauPET tracer diagnostic.

TODAY'S FREE FLY STORIES

PAYS

Paysign

$11.27

-0.56 (-4.73%)

20:32
11/14/19
11/14
20:32
11/14/19
20:32
Initiation
Paysign initiated at DA Davidson »

Paysign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 25

    Nov

  • 26

    Nov

LPTX

Leap Therapeutics

$0.57

-0.5922 (-50.83%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Downgrade
Leap Therapeutics rating change at Raymond James »

Leap Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$100.07

0.38 (0.38%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Upgrade
Fortinet rating change at Credit Suisse »

Fortinet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 18

    Nov

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

JD

JD.com

$33.57

0.21 (0.63%)

, WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JD

JD.com

$33.57

0.21 (0.63%)

WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

RYTM

Rhythm Pharmaceuticals

$21.52

0.38 (1.80%)

JCP

J.C. Penney

$1.10

0.01 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 09

    Dec

SBS

Sabesp

$12.21

-0.02 (-0.16%)

20:22
11/14/19
11/14
20:22
11/14/19
20:22
Earnings
Sabesp reports Q3 adjusted EBITDA up 109.8% at BRL3.01B »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

LINX

Linx S.A.

$7.11

-0.8 (-10.11%)

19:16
11/14/19
11/14
19:16
11/14/19
19:16
Recommendations
Linx S.A. analyst commentary at Jefferies »

Linx S.A. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CNP

CenterPoint Energy

$26.68

-1.42 (-5.05%)

19:12
11/14/19
11/14
19:12
11/14/19
19:12
Downgrade
CenterPoint Energy rating change at Credit Suisse »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$309.54

0.46 (0.15%)

19:09
11/14/19
11/14
19:09
11/14/19
19:09
Periodicals
Kudlow says U.S. near trade agreement with China, Reuters says »

White House economic…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$309.54

0.46 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$75.55

-0.54 (-0.71%)

18:41
11/14/19
11/14
18:41
11/14/19
18:41
Hot Stocks
BioMarin CEO: Our products have a very long life cycle »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

18:38
11/14/19
11/14
18:38
11/14/19
18:38
Periodicals
Judge rejects Icahn's suit seeking Occidental acquisition records, Reuters says »

A Delaware court judge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

, DGII

Digi International

$15.10

0.33 (2.23%)

18:35
11/14/19
11/14
18:35
11/14/19
18:35
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

DGII

Digi International

$15.10

0.33 (2.23%)

AMAT

Applied Materials

$56.89

-0.24 (-0.42%)

KLIC

Kulicke & Soffa

$25.18

-0.22 (-0.87%)

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

WPM

Wheaton Precious Metals

$26.47

-0.12 (-0.45%)

RDNT

RadNet

$15.92

0.09 (0.57%)

RH

RH

$175.19

1.98 (1.14%)

ACB

Aurora Cannabis

$3.29

-0.25 (-7.06%)

OSMT

Osmotica Pharmaceuticals

$4.00

-0.03 (-0.74%)

GLOB

Globant

$108.99

3.975 (3.79%)

DLB

Dolby

$65.56

-0.14 (-0.21%)

NVDA

Nvidia

$209.88

1.33 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 06

    Jan

VIA

Viacom

$25.31

0.175 (0.70%)

, VIAB

Viacom

$22.48

0.44 (2.00%)

18:24
11/14/19
11/14
18:24
11/14/19
18:24
Hot Stocks
Viacom CEO: The road ahead for the company is very exciting »

In an interview on…

VIA

Viacom

$25.31

0.175 (0.70%)

VIAB

Viacom

$22.48

0.44 (2.00%)

CBS

CBS

$37.62

0.78 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 09

    Dec

NVDA

Nvidia

$209.88

1.33 (0.64%)

18:22
11/14/19
11/14
18:22
11/14/19
18:22
Hot Stocks
Breaking Hot Stocks news story on Nvidia »

Nvidia CFO says continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

NVDA

Nvidia

$209.88

1.33 (0.64%)

18:04
11/14/19
11/14
18:04
11/14/19
18:04
Hot Stocks
Nvidia CEO says Q4 will be much stronger driven by AI and inference »

Says computational…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

BABA

Alibaba

$182.69

0.21 (0.12%)

17:50
11/14/19
11/14
17:50
11/14/19
17:50
Syndicate
Alibaba launches Hong Kong IPO »

Alibaba Group Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Conference/Events
William Blair SaaS analyst to hold a luncheon meeting »

SaaS Analyst Pfau holds a…

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Earnings
Helmerich & Payne sees FY20 CapEx approximately $275M-$300M »

57-62% expected for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

PPG

PPG

$129.82

-0.5 (-0.38%)

, PG

Procter & Gamble

$120.49

-0.15 (-0.12%)

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Hot Stocks
Trian Fund exits PPG, cuts Wendy's in Q3 »

Nelson Peltz' Trian…

PPG

PPG

$129.82

-0.5 (-0.38%)

PG

Procter & Gamble

$120.49

-0.15 (-0.12%)

MDLZ

Mondelez

$52.90

0.2 (0.38%)

LM

Legg Mason

$38.60

-0.22 (-0.57%)

GE

General Electric

$11.30

-0.01 (-0.09%)

WEN

Wendy's

$20.90

-0.01 (-0.05%)

BK

BNY Mellon

$48.42

0.07 (0.14%)

SYY

Sysco

$81.51

0.27 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 02

    Dec

  • 11

    Dec

  • 16

    Jan

  • 29

    Jan

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

17:48
11/14/19
11/14
17:48
11/14/19
17:48
Earnings
Helmerich & Payne reports Q4 cont ops EPS 38c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

17:47
11/14/19
11/14
17:47
11/14/19
17:47
Conference/Events
DA Davidson software analysts to hold a dinner meeting »

Analysts host a Security…

MDCO

The Medicines Co.

$50.89

-1.905 (-3.61%)

17:46
11/14/19
11/14
17:46
11/14/19
17:46
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

NVDA

Nvidia

$209.88

1.33 (0.64%)

17:44
11/14/19
11/14
17:44
11/14/19
17:44
Hot Stocks
Nvidia CFO says Q3 decline in automotive revenue driven by one-time item »

Says AI cockbit business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

, PSDO

Presidio

$16.56

-0.02 (-0.12%)

17:44
11/14/19
11/14
17:44
11/14/19
17:44
Hot Stocks
Paulson adds Callon Petroleum, lowers stake in Lyft in Q3 »

John Paulson's…

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

PSDO

Presidio

$16.56

-0.02 (-0.12%)

OSG

Overseas Shipholding

$1.84

0.045 (2.51%)

STC

Stewart

$43.10

0.11 (0.26%)

AGN

Allergan

$182.47

0.91 (0.50%)

HZNP

Horizon Pharma

$29.82

-0.48 (-1.58%)

ONCE

Spark Therapeutics

$110.78

-0.65 (-0.58%)

MYL

Mylan

$17.26

-0.01 (-0.06%)

S

Sprint

$5.86

-0.21 (-3.46%)

LYFT

Lyft

$41.90

-1.39 (-3.21%)

TMUS

T-Mobile

$76.87

-1.15 (-1.47%)

PCG

PG&E

$6.70

-0.19 (-2.76%)

WCG

WellCare

$301.86

-2.56 (-0.84%)

TSU

Tim Participacoes

$15.53

0.44 (2.92%)

GLD

SPDR Gold Shares

$138.57

0.59 (0.43%)

BHC

Bausch Health

$27.77

0.38 (1.39%)

CELG

Celgene

$110.03

-0.42 (-0.38%)

DISCK

Discovery Inc.

$28.04

0.12 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 07

    Jan

  • 25

    Mar

  • 04

    Apr

17:41
11/14/19
11/14
17:41
11/14/19
17:41
Conference/Events
BTIG energy analysts to hold a luncheon »

Energy Analysts host…

17:40
11/14/19
11/14
17:40
11/14/19
17:40
Conference/Events
Wolfe Research tech strategist to hold analyst/industry webcast »

Tech Strategist…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.